Amarin Corp. (AMRN) – Insiders' Blog
-
PDUFA, FDA Panel Review Dates at Risk with Gov't Shutdown (AMRN) (LGND)
-
Pfizer (PFE), Amgen (AMGN) Duke it Out for Takeover of Cancer Drug Maker Biocad
-
Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
-
Amarin (AMRN) Up as Vascepa Shows Strong Rx Growth Last Week
-
Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
-
Amarin (AMRN) Vascepa Exclusivity Status Not in FDA Orange Book March Update
-
Amarin (AMRN) Lower as Competitor Omthera Pharma (OMTH) Files IPO
-
Amarin (AMRN) Vascepa Pricing Leak?
-
Amarin (AMRN) Higher as Teva (TEVA) Said to be Waiting in the Wings for a Takeover
-
Another Case Made for Amarin's (AMRN) Vascepa Missing NCE Status
-
Amarin (AMRN) Drops Most in 7 Months as FDA Makes No Determination on Vascepa
-
Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again
-
Amarin Corp. (AMRN) Ticks Higher Following NoA for '408 App
-
Amarin Corp (AMRN) Trades Higher Again Following USPTO NoA Publication on Two Apps
-
Amarin (AMRN) Is 'In Play'
-
Amarin (AMRN) Investors Look Beyond NCE Status and to a Buyout
-
Amarin (AMRN) Volatility Nearly Double into PDUFA for AMR101
-
Amarin (AMRN) Volatility Elevated with Shares at Intraday Lows
-
Amarin Corp. (AMRN) Shares Pop on Boosted Target, Positive Analyst Comments
-
UPDATE: Amarin (AMRN) Shares Pop Higher as Real M&A Speculates on Takeover
-
Amarin (AMRN) Produces Drugs Faster than It Can Get Patents
-
Amarin (AMRN) IP Chief to Depart Company as AMR101 Exclusivity Still in Air
Back to AMRN Stock Lookup